Clinical-pathological Evaluation of Pit-NETs

Not yet recruitingOBSERVATIONAL
Enrollment

940

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2026

Conditions
PituitaryCancerNeuroendocrine Tumors
Interventions
DIAGNOSTIC_TEST

grading & staging

To investigate the following pathological features of PitNET cell lineage-specific transcription factors, cell type specification by hormone production, proliferative index, p53, mitotic count, expression of somatostatin receptors

DIAGNOSTIC_TEST

PitNET morphology analysis

Revision of the pre-surgical magnetic resonance images (MRIs): tumor maximum diameter, volume, sites of tumor extensions and invasion, and grading of cavernous sinus invasion

DIAGNOSTIC_TEST

Radiomics

To investigate radiomics features of PitNETs

DIAGNOSTIC_TEST

Molecular test: proteomics

To investigate on PitNets of molecular biomarkers Vascular Endothelial Growth Factor (VEGF), Epithelial Growth Factor Receptor (EGFR), somatostatin receptors 1-5 (SSTRs), Fibroblast Growth Factor (FGF), mTOR (mammalian target of rapamycin), Programmed cells Death 1 (PD1) and its ligands (PD-L1), and Cytotoxic T Lymphocyte Associated protein 4 (CTLA4)\]

Trial Locations (1)

00168

Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC ANATOMIA PATOLOGICA, Rome

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT06607198 - Clinical-pathological Evaluation of Pit-NETs | Biotech Hunter | Biotech Hunter